Wedbush Reiterates Outperform on Cidara Therapeutics (CDTX) Following 2Q
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/11/2026
- Wall Street ends down as US-Iran peace optimism fades
- S&P 500 EPS growth above 20% is rare. Why 2027 may be at risk
- Goldman Sachs warns AI investment may be crowding out other business spending
- Why Wednesday's inflation print could provide the next dovish catalyst
- Tesla needs Robotaxi flywheel proof to boost investor conviction: Morgan Stanley
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Streetinsider.com's Hot Lunchtime Reads 8/15: (TWTR) (FIT) (MU) (HRB)
August 15, 2016 12:03 PM EDTThe following is a list of notable articles to help get you through the lunch hour:Twitter (TWTR) calls active on reports about bringing Twitter app to Apple TV ->... More
BTIG Expects More Visibility for Cidara Therapeutics' (CDTX) CD101 Soon; Affirms at 'Buy'
August 15, 2016 11:48 AM EDTBTIG affirms Cidara Therapeutics, Inc. (Nasdaq: CDTX) at Buy with a price target of $24 following recent quarterly results and CD101 update.
Analyst Timothy Chiang commented, We expect more visibility on the Co.s novel echinocandin (antifungal) product candidate, CD101, by early 2017 when... More
Needham & Company Reiterates Buy on Cidara Therapeutics (CDTX) Following 2Q Report
August 15, 2016 8:19 AM EDTNeedham & Company reiterated a Buy rating and $20.00 price target on Cidara Therapeutics (NASDAQ: CDTX) following the release of company's 2Q16 financial results and management updates. The Phase 2 non-inferiority STRIVE trial of IV CD101 in Candidemia (NCT02734862) is expected to enroll 90 patients, randomized 1:1:1 to standard... More
